The latest episode of Optimum Perspectives Podcast has just dropped, featuring LoQus23 Therapeutics’ Chief Scientific Officer and founder Caroline Benn! Listen as Caroline details the devastating effects of Huntington’s Disease on patients and families, her personal motivations for working in this therapeutic area, as well as LoQus23’s unique approach to battling the disease through their innovative small molecule approach. Hosted on Acast. See acast.com/privacy for more information....
Aug 05, 2025•23 min•Ep. 34
On the latest episode of the Optimum Perspectives podcast, Optimum Strategic Communications’ Managing Director Eva Haas spoke with Curve Therapeutics CSO and Co-Founder Ali Tavassoli, who has today been awarded the Royal Society of Chemistry’s Interdisciplinary Prize. Listen below as Ali reflects on his scientific journey which has led him to this tremendous recognition, from what inspired his passion for science, to how he came to meet Curve CEO Simon Kerry, with whom he co-founded the Company....
Jun 25, 2025•24 min•Ep. 33
Listen to our Rare Disease Day Optimum Perspecitives podcast special featuring Tahira Mathur, Patient Advocate and Kate Adcock, Director of Research & Innovation at Optimum's chosen charity Muscular Dystrophy UK, alongside Jasper Morrow, consultant neurologist at University College London Hospital. This emotional yet hopeful episode highlights the importance of raising awareness of rare conditions, while discussing patient care, diagnosis, and genetic testing for Muscular Dystrophy. If you w...
Feb 28, 2025•30 min•Ep. 32
Want to know how bioengineered spider silk protein fibres can be applied within the textile, biomedical and automobile industries? In the latest episode of Optimum Perspectives, hear from Benoit Cugnet, Head of Fiber Business Unit at AMSilk, on how this German biotech is changing the face of advanced materials. Hosted on Acast. See acast.com/privacy for more information.
Feb 06, 2025•12 min•Ep. 31
Want to know how to prepare yourself for the perfect IPO on NASDAQ? Hear from Lynn Lewis, CEO of Gilmartin Group, Optimum’s US partner, on the considerations and milestones to reach before listing. Hosted on Acast. See acast.com/privacy for more information.
Jan 23, 2025•24 min•Ep. 30
The latest epiosde of Optimum Perspectives Podcast features Germo Gericke, CMO of Ariceum Therapeutics. Listen as he discusses how the company aims to improve outcomes for patients with lung cancer with radioligand therapy this Lung Cancer Awareness Month. Hosted on Acast. See acast.com/privacy for more information.
Nov 27, 2024•10 min•Ep. 29
Great new insights in the Optimum Perspectives' latest podcast edition featuring Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics, about the growing role of B cell technology in cancer therapy. Hosted on Acast. See acast.com/privacy for more information.
Nov 21, 2024•9 min•Ep. 28
In this podcast to mark Lung Cancer Awareness Month, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of Disco Pharmaceuticals, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology. Hosted on Acast. See acast.com/privacy for more information.
Nov 05, 2024•16 min•Ep. 27
Optimum’s Richard Staines talks to Feride Sahin, Senior Director of Clinical Development at Splice Bio about the importance of World Sight Day, which takes place this week. Hosted on Acast. See acast.com/privacy for more information.
Oct 10, 2024•12 min•Ep. 26
It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer drug with the help of a tumour-targeting antibody, find out more in this episode featuring Heidelberg Pharma's CEO, Andreas Pahl. Hosted on Acast. See acast.com/privacy for more information.
Sep 12, 2024•14 min•Ep. 25
Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the company’s technology based around pro-regenerative macrophages and its potential to treat liver disease. Hosted on Acast. See acast.com/privacy for more information.
Aug 08, 2024•28 min•Ep. 24
Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In this episode Optimum’s Eva Haas discusses the highlights of Ruth’s incredible career, the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer's in recent years. Hosted on Acast. See acast.com/privacy for more information.
Jul 25, 2024•22 min•Ep. 23
Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, CEO of Poolbeg Pharma. Hosted on Acast. See acast.com/privacy for more information.
May 30, 2024•24 min•Ep. 22
Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round. In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”. He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programm...
May 23, 2024•13 min•Ep. 21
Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how to succeed in the new wave of biotech IPOs in the Optimum Perspectives podcast. Hosted on Acast. See acast.com/privacy for more information.
May 16, 2024•21 min•Ep. 20
Check out Optimum’s latest Optimum Perspectives Podcast episode featuring the stars of the 20th Anglonordic Life Science Conference in London. Hear industry leaders give their thoughts on trends within the life science industry and the optimistic mood of the markets in 2024! Hosted on Acast. See acast.com/privacy for more information.
May 07, 2024•9 min•Ep. 19
Diverse recruitment for clinical trials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum’s Richard Staines as he discuses this thorny issue with Ariceum Therapeutic’s CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Non-Executive Director & Thought Leader Annalisa Jenkins. Hosted on Acast. See acast.com/privacy for more information.
Apr 04, 2024•24 min•Ep. 18
Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the company's lead candidate LTX-315 has a unique approach to killing cancer. Hosted on Acast. See acast.com/privacy for more information.
Mar 07, 2024•17 min•Ep. 17
To mark Rare Disease Day on 29 February, Optimum Perspectives podcast interviews a panel of experts who discuss the opportunities and challenges for developers of therapies for rare diseases in 2024. Hosted on Acast. See acast.com/privacy for more information.
Feb 29, 2024•38 min•Ep. 16
In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry. Chaired by esteemed journalist Lisa Urquhart, hear guest speakers Renee Aguiar-Lucander of Calliditas, Lene Gerlach of EIR Ventures & WiLD, Bita Sehat of Trill Impact, and Ninna Struck Rossen of Metsystem, share their stories on being women in life sciences, and how to succeed i...
Feb 08, 2024•28 min•Ep. 15
Happy 1st birthday to the Optimum Perspectives Podcast! Since launching, 1000s of listens have grown the show into an excellent hub of intel from top tier life science guests. Listen now to our anniversary special, where Optimum's Mary Clark, Nick Bastin and Eva Haas discuss the findings of our insightful European Life Sciences Investor survey! Hosted on Acast. See acast.com/privacy for more information.
Jan 23, 2024•18 min•Ep. 14
Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function. Hosted on Acast. See acast.com/privacy for more information.
Dec 12, 2023•11 min•Ep. 13
In this insightful and emotional podcast episode, the co-founder of Ariana Smiles - a Special Named Fund at CCLG UK, Stephanie Seales Gabbitas shares her mission to improve the lives of children diagnosed with Leukaemia by raising funds for research into precision oncology medicine. Hosted on Acast. See acast.com/privacy for more information.
Dec 06, 2023•16 min•Ep. 12
There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimum Strategic Communications’ Eva Haas about the Company’s potential new maintenance therapy Kinselby (resminostat). 4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL). It has developed Kinselby (resminostat), a novel, oral, maintenance treatment targeting advanced-CTCL, a rare type o...
Nov 21, 2023•18 min•Ep. 11
Optimum celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! In the latest episode of Optimum Perspectives Podcast, Richard Staines talks through the top takeaways from the October event with special testimonials from our guests. Hosted on Acast. See acast.com/privacy for more information.
Nov 02, 2023•9 min•Ep. 10
Episode 9 of Optimum Perspectives Podcast features Optimum's Richard Staines and Eva Haas, who discuss the hot areas for investment in the shifting biotech market – including antibody-drug conjugates, smart radiotherapies, mRNA and immune-oncology. Want us to explore a topic further? Let us know! Hosted on Acast. See acast.com/privacy for more information.
Sep 07, 2023•14 min•Ep. 9
Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach. Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are associated with. Optimum Strategic Communications’ Richard Staines caught up with Alchemab’s CEO, Young Kwon ,...
Aug 22, 2023•18 min•Ep. 8
No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma . Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find out how Poolbeg is using AI to expedite discovery of new flu drugs. Poolbeg is working on a drug that aims to block some of the worst effects of influenza, neutralising the over-reaction from the body’s immune system known as a “cytokine storm” that produces many of th...
Aug 08, 2023•16 min•Ep. 7
A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In its latest podcast, Optimum Strategic Communications caught up with Chris Martin, Senior Vice President of Commercial, who discussed how the company plans to launch this potential novel COPD medicine. Hosted on Acast. See acast.com/privacy for more information....
Jul 24, 2023•18 min•Ep. 6
Today’s funding environment for small biotechs is tough. Valuations are down and money is tighter than it used to be – both for publicly listed and privately held firms. In these circumstances, obtaining the right backing – both in terms of finance and managerial advice – is more important than ever. In the fifth Optimum Perspectives podcast experienced investor Søren Møller talks to Optimum’s Stephen Adams about Novo Holdings Seed Investments ’ approach to working with biotechs and what early-s...
Jun 26, 2023•21 min•Ep. 5
